HeadaTerm TENS device was shown to provide fast treatment for acute migraine in a study. Credit: WAT Medical

WAT Medical has announced that the HeadaTerm TENS device in a clinical study reduced acute migraine pain 11.8% more than any other migraine medications.

HeadaTerm, which provides drug-free treatment without side effects, can be worn on the user’s forehead, using non-invasive neuronal electrical stimulation technology to prevent and treat primary headache, including migraine.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Comprising a blind, randomised controlled trial, the study was conducted by Dr Nihat M Hokenek and his team at the Emergency Department of Kartal Dr Lütfi Kirdar Training and Research Hospital in Istanbul, Turkey.

The study divided patients into a control group and a verum group, which included patients using the device for the first time, with identical devices allocated to both the groups, each undergoing 20 minutes of therapy.

After therapy initiation, patients’ perceived changes in the pain intensity were recorded at the 20 and 120-minute marks, using Visual Analogue Scale (VAS), with the individual need for the additional treatments evaluated for patients after 120 minutes.

While the VAS change for the verum group from 0 to 120 minutes recorded -65.46 ± 25.11, it was -9.46 ± 2.61 (p <0.001) for the control group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Verbal scores in the 120-minute mark were 1.2 for the control group and 4.5 for the verum group.

Furthermore, more analgesic requirement for 30 patients (76.92%) in the control group was required, as well as 1 (2%) in the verum group, after 120 minutes.

The study found that TENS therapy is a fast-acting treatment for acute migraine.